Form 8-K - Current report:
SEC Accession No. 0001193125-25-263540
Filing Date
2025-11-04
Accepted
2025-11-04 07:10:25
Documents
12
Period of Report
2025-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kymr-20251104.htm   iXBRL 8-K 57280
2 EX-99.1 kymr-ex99_1.htm EX-99.1 154395
3 GRAPHIC img100385778_0.jpg GRAPHIC 70537
  Complete submission text file 0001193125-25-263540.txt   438147

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kymr-20251104.xsd EX-101.SCH 31101
14 EXTRACTED XBRL INSTANCE DOCUMENT kymr-20251104_htm.xml XML 4716
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 251446423
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)